14 February 2025
15 February 2025
14 February 2025
Registration
Official opening
Voice of the Patient: Organization in the Pathway of the Patient with Breast Cancer in Bulgaria
Gergana Bogdanova (One of 8), Dr. Stanimir Kacheshmarov (GP), Assoc. Prof. Dr. Assia Konsoulova (BJCN)
Symposium, supported by the industry – Novartis
When, how and how much in breast cancer
Moderator: Assoc. Prof. Dr. Dimitar Kalev
Multidisciplinary scientific discussion panel:
Moderator: Assoc. Prof. Dr. Dimitar Kalev
Multidisciplinary scientific discussion panel:
- Assessment of the risk of recurrence in early breast cancer
- Modern guidelines in breast cancer staging
- The role of some additional factors Panelists: Assoc. Prof. Dr. Assia Konsoulova, Dr. Vanya Mitova, Dr. Margarita Taushanova
SABCS® 2024 Module 1
Moderator: Prof. Dr. Savelina Popovska
15:35 – 15:50 Genomic prediction in early and metastatic breast cancer
Lyubomir Balabanski
15:50 – 16:05 Biomarkers in early breast cancer
Prof. Dr. Savelina Popovska
16:05 – 16:25 Immuno-oncology in early breast cancer
Assoc. Prof. Dr. Zhelyazko Arabadzhiev
16:25 – 16:40 Debate: High-risk early breast cancer should be routinely screened for recurrence using ctDNA, TILs and other markers
Prof. Dr. Savelina Popovska, Assoc. Prof. Dr. Zhelyazko Arabadzhiev, Lyubomir Balabanski
Lyubomir Balabanski
15:50 – 16:05 Biomarkers in early breast cancer
Prof. Dr. Savelina Popovska
16:05 – 16:25 Immuno-oncology in early breast cancer
Assoc. Prof. Dr. Zhelyazko Arabadzhiev
16:25 – 16:40 Debate: High-risk early breast cancer should be routinely screened for recurrence using ctDNA, TILs and other markers
Prof. Dr. Savelina Popovska, Assoc. Prof. Dr. Zhelyazko Arabadzhiev, Lyubomir Balabanski
Coffee break
SABCS® 2024 Module 2
Moderator: Assoc. Prof. Dr. Assia Konsoulova
17:10 – 17:30 Indicators and interventions for monitoring breast cancer
Dr. Dimo Manov
17:30 – 17:40 Debate: Body weight parameters should be monitored in breast cancer survivors
Assoc. Prof. Dr. Assia Konsoulova, Dr. Dimo Manov
Dr. Dimo Manov
17:30 – 17:40 Debate: Body weight parameters should be monitored in breast cancer survivors
Assoc. Prof. Dr. Assia Konsoulova, Dr. Dimo Manov
Symposium, supported by the industry – MSD
Modern multidisciplinary approach to the treatment of
breast cancer
Moderator: Assoc. Prof. Dr. Assia Konsoulova News from San Antonio on early stages of breast cancer
Dr. Dimo Manov
How the behavior of the surgeon is changing in the diagnostic and treatment approach in triple negative breast cancer
Dr. Vulkan Ivanov
Moderator: Assoc. Prof. Dr. Assia Konsoulova News from San Antonio on early stages of breast cancer
Dr. Dimo Manov
How the behavior of the surgeon is changing in the diagnostic and treatment approach in triple negative breast cancer
Dr. Vulkan Ivanov
Dinner
15 February 2025
Registration
SABCS® 2024 Module 3
Moderator: Assoc. Prof. Dr. Assia Konsoulova
09:00 – 09:15 Image-derived AI-based prognostic models and axillary ultrasound
Dr. Viktor Yordanov
09:15 – 09:45 Surgical axillary staging of early breast cancer
Dr. Valkan Ivanov
09:45 – 10:00 Debate: In every early breast cancer, criteria should be defined for possible avoidance of surgical axillary staging
Assoc. Prof. Dr. Assia Konsoulova, Dr. Valkan Ivanov, Dr. Viktor Yordanov
Dr. Viktor Yordanov
09:15 – 09:45 Surgical axillary staging of early breast cancer
Dr. Valkan Ivanov
09:45 – 10:00 Debate: In every early breast cancer, criteria should be defined for possible avoidance of surgical axillary staging
Assoc. Prof. Dr. Assia Konsoulova, Dr. Valkan Ivanov, Dr. Viktor Yordanov
Symposium, supported by the industry – AstraZeneca
A Step Forward in the Treatment of Breast Cancer – What
We Learned from the San Antonio Breast Cancer Symposium
Moderator: Assoc. Prof. Dr. Assia Konsoulova
A Step Forward in Early gBRCAm Breast Cancer
Dr. Margarita Taushanova
The Next Step in the Treatment of Advanced Breast Cancer
Dr. Bozhidara Kostova
Moderator: Assoc. Prof. Dr. Assia Konsoulova
A Step Forward in Early gBRCAm Breast Cancer
Dr. Margarita Taushanova
The Next Step in the Treatment of Advanced Breast Cancer
Dr. Bozhidara Kostova
Coffee break
SABCS® 2024 Module 4
Moderator: Assoc. Prof. Dr. Assia Konsoulova
11:10 – 11:50 Risk/biomarker-based systemic therapy in early breast cancer
Dr. Dimo Manov
11:50 – 12:05 Debate: In every early HR+/HER2– breast cancer, a genomic risk assessment should be performed to refine the perioperative therapy
Assoc. Prof. Dr. Assia Konsoulova, Dr. Dimo Manov
Dr. Dimo Manov
11:50 – 12:05 Debate: In every early HR+/HER2– breast cancer, a genomic risk assessment should be performed to refine the perioperative therapy
Assoc. Prof. Dr. Assia Konsoulova, Dr. Dimo Manov
Symposium, supported by the industry – Swixx BioPharma
Shaping the Future: What Are the Prospects for
Antibody-Drug Conjugates
Current Principles of Treatment and the Place of Antibody- Drug Conjugates
Dr. Tsvetan Yordanov
The Future of Antibody-Drug Conjugates
Dr. Petya Balikova
Current Principles of Treatment and the Place of Antibody- Drug Conjugates
Dr. Tsvetan Yordanov
The Future of Antibody-Drug Conjugates
Dr. Petya Balikova
Lunch
SABCS® 2024 Module 5
Moderator: Assoc. Prof. Dr. Assia Konsoulova
14:00 – 14:40 Risk-based radiotherapy in early breast cancer
Dr. Dorotea Ivanova
14:40 – 14:55 Debate: The degree of risk should be considered for personalization of radiotherapy strategies in DCIS and early luminal breast cancer
Assoc. Prof. Dr. Assia Konsoulova, Dr. Dorotea Ivanova
Dr. Dorotea Ivanova
14:40 – 14:55 Debate: The degree of risk should be considered for personalization of radiotherapy strategies in DCIS and early luminal breast cancer
Assoc. Prof. Dr. Assia Konsoulova, Dr. Dorotea Ivanova
Symposium, supported by the industry – Pfizer
Results from the largest comparative analysis of the three CDK4/6-
inhibitors P-VERIFY and other highlights from SABCS 2024
Assoc. Prof. Dr. Assia Konsoulova
Assoc. Prof. Dr. Assia Konsoulova
Symposium, supported by the industry – Eli Lilly
Therapeutic approach in patients with hormone-positive,
HER2-negative early breast cancer at high risk
Real-world experience in the therapy of patients with HR+/HER2– early breast cancer at high risk of recurrence
Dr. Margarita Tauschanova
Real-world experience in the therapy of patients with HR+/HER2– early breast cancer at high risk of recurrence
Dr. Margarita Tauschanova
Coffee break
SABCS® 2024 Module 6
Moderator: Assoc. Prof. Dr. Assia Konsoulova
16:30 – 17:10 New targeted strategies for systemic therapy in metastatic breast cancer
Dr. Petya Balikova
17:10 – 17:25 Debate: Are there limits to co-targeting in co-positive metastatic breast cancer
Assoc. Prof. Dr. Assia Konsoulova, Dr. Petya Balikova
Dr. Petya Balikova
17:10 – 17:25 Debate: Are there limits to co-targeting in co-positive metastatic breast cancer
Assoc. Prof. Dr. Assia Konsoulova, Dr. Petya Balikova
Expert opinion of the Bulgarian Joint Cancer Network:
Changes in clinical practice from Monday
Assoc. Prof. Dr. Assia Konsoulova
